The Risk Stratification and Treatment of Chronic Kidney Disease in Women: Uncovering and Addressing Disparities to Improve Outcomes

This activity consists of a recorded presentation at the 2024 Women's Health and Wellness Masterclass, held in April 2024 in Dana Point, CA.  The symposium, "The Risk Stratification and Treatment of Chronic Kidney Disease in Women: Uncovering and Addressing Disparities to Improve Outcomes" was presented by Pam R. Taub, MD, Erin D. Michos, MD, and Jennifer Green, MD. 

Target Audience

The educational design of this activity addresses the needs of US-based healthcare professionals, including endocrinologists, cardiologists, internists, primary care clinicians, obstetricians, pharmacists, physicians, nurse practitioners, and physician assistants.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Recognize the burden of CKD as a major driver of cardiovascular and renal morbidity and mortality in women
  • Review conventional and women-specific risk factors for CKD progression in women 
  • Identify women at risk for kidney disease or kidney disease progression based on recommended diagnostic practices
  • Review the efficacy and safety with SGLT2 inhibitors for patients with or at-risk for CKD
  • Discuss practical considerations for the application of SGLT2 inhibitors to improve renal outcomes in women with or at-risk for CKD
  • Select tailored treatment regimens that reduce the risk of renal and cardiovascular events in women with or at-risk for CKD
Course summary
Available credit: 
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
07/03/2024
Course expires: 
07/03/2025
Rating: 
0

Pam R. Taub MD, FACC (Chair)
Founder and Director of Step Family Cardiac Rehabilitation and Wellness Center
Director of Preventive Cardiology
Professor of Medicine
UC San Diego Health System

Jennifer Green, MD
Professor of Medicine, Division of Endocrinology
Duke Clinical Research Institute
Duke University School of Medicine

 
Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC
Director of Women’s Cardiovascular Health Research
Associate Director of Preventive Cardiology
Associate Professor of Medicine and Epidemiology
Division of Cardiology
Johns Hopkins School of Medicine
Co-Editor in Chief, the American Journal of Preventive Cardiology

ESTIMATED TIME TO COMPLETE ACTIVITY
1 hour

EDUCATIONAL GRANT SUPPORT

Supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

JOINT PROVIDERSHIP STATEMENT
A picture containing text, clipart Description automatically generated

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC).  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING EDUCATION

PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CONTINUING EDUCATION

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0  contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.

PHARMACY CONTINUING EDUCATION

PACE designates this continuing education activity for 1.0  contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-24-163-H01-P. Type of activity: Application

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

METHOD OF PARTICIPATION & REQUEST FOR CREDIT

There are no registration fees for this activity. Participation in this self-study activity should be completed in approximately 1.0 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from July 3, 2024 through July 3, 2025.

  1. Review the objectives and disclosures
  2. Study the educational content
  3. Successfully complete activity post-test(s)
  4. Complete the activity evaluation

You must receive a test score of at least 75% and respond to all evaluation questions to receive a certificate. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org. For additional information about the accreditation of this activity, please visit https://partnersed.com

DISCLOSURES

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr. Green, faculty for this educational activity, discloses the following:

  • Consultant, Advisor, Speaker: Boehringer Ingelheim, Eli Lilly, Bayer, Novo Nordisk, AstraZeneca, Pfizer, Anji, Vertex, Valo
  • Researcher: Boehringer Ingelheim, Eli Lilly, Merck, Roche

Dr. Michos, faculty for this educational activity, discloses the following:

  • Consultant, Advisor, Speaker: Amgen, AstraZeneca, Boehringer Ingelheim, Edwards Lifescience, Esperion, Medtronic, Merck, Novo Nordisk, Novartis, New Amsterdam, Pfizer

Dr. Taub, faculty for this educational activity, discloses the following:

  • Consultant, Advisor, Speaker: Amgen, Boehringer Ingelheim/Lilly, Novartis, Novo Nordisk, Esperion, Medtronic, Edwards, Sanofi

DISCLOSURE OF UNLABELED USE 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

DISCLAIMER 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Available Credit

  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.

Required Hardware/software

A computer with an internet connection

Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser

Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.